FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.The Motley Fool • Tuesday
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung CancerBusiness Wire • Monday
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the StockZacks Investment Research • 11/02/26
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 GuidanceBusiness Wire • 10/29/26
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply AgreementBusiness Wire • 10/28/26
Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic CancerBusiness Wire • 10/01/26
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?Zacks Investment Research • 08/28/26
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great ChoiceZacks Investment Research • 08/20/26
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a BetZacks Investment Research • 08/12/26
NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 07/27/26
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to TradeZacks Investment Research • 07/27/26
Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and ProspectsZacks Investment Research • 07/27/26